Free tool
FAERS Monitor: Kepivance
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125103 or its brand name (Kepivance, Palifermin). Reports on generic versions are filed under their own applications.
Reports
389
Serious
351
90% of reports
Hospitalization
154
Death reported
67
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- mucosal inflammation56
- febrile neutropenia39
- rash39
- stomatitis34
- erythema28
- sepsis24
- pyrexia23
- diarrhoea20
- neutropenia20
- infection19
- oedema peripheral19
- off label use19
- pruritus19
- pain17
- skin exfoliation17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 23 |
| 2006 | 60 |
| 2007 | 60 |
| 2008 | 55 |
| 2009 | 17 |
| 2010 | 2 |
| 2011 | 9 |
| 2012 | 4 |
| 2013 | 7 |
| 2014 | 4 |
| 2015 | 19 |
| 2016 | 19 |
| 2017 | 47 |
| 2018 | 16 |
| 2019 | 8 |
| 2020 | 11 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 7 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,770 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mucosal inflammationSignal | 56 | 115.9 | 90.9 | 6,259 |
| febrile neutropeniaSignal | 39 | 31.8 | 23.6 | 1,136 |
| stomatitisSignal | 34 | 30.3 | 22.0 | 937 |
| sepsisSignal | 24 | 11.6 | 7.9 | 224 |
| skin exfoliationSignal | 17 | 10.9 | 6.8 | 144 |
| oedema peripheralSignal | 19 | 8.4 | 5.4 | 118 |
| neutropeniaSignal | 20 | 8.0 | 5.2 | 115 |
| erythemaSignal | 28 | 7.4 | 5.2 | 149 |
| infectionSignal | 19 | 7.1 | 4.6 | 94 |
| rashSignal | 39 | 4.8 | 3.6 | 117 |
| pyrexiaSignal | 23 | 3.6 | 2.4 | 41 |
| pruritusSignal | 19 | 2.7 | 1.7 | 19 |
| diarrhoea | 20 | 1.7 | 1.1 | 5 |
| pain | 17 | 1.5 | 0.9 | 2 |
| off label use | 19 | 1.2 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.